Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

Maria Cubero; Juan Ignacio Esteban; Teresa Otero; Silvia Sauleda; Marta Bes; Rafael Esteban; Jaume Guardia; Josep Quer

doi:10.1016/j.virol.2007.10.006

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

Maria Cubero, Juan Ignacio Esteban, Teresa Otero, Silvia Sauleda, Marta Bes, Rafael Esteban, Jaume Guardia, Josep Quer

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

68 Citations (Scopus)

Abstract

An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. © 2007 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	237-245
Journal	Virology
Volume	370
Issue number	2
DOIs	https://doi.org/10.1016/j.virol.2007.10.006
Publication status	Published - 20 Jan 2008

Keywords

HCV-NS3
Inhibitor
Mutant
Patient
Resistant
Untreated

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virol.2007.10.006

Cite this

@article{3e59747dbe634ab18907ff35a006d41b,

title = "Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient",

abstract = "An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. {\textcopyright} 2007 Elsevier Inc. All rights reserved.",

keywords = "HCV-NS3, Inhibitor, Mutant, Patient, Resistant, Untreated",

author = "Maria Cubero and Esteban, {Juan Ignacio} and Teresa Otero and Silvia Sauleda and Marta Bes and Rafael Esteban and Jaume Guardia and Josep Quer",

year = "2008",

month = jan,

day = "20",

doi = "10.1016/j.virol.2007.10.006",

language = "English",

volume = "370",

pages = "237--245",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

AU - Cubero, Maria

AU - Esteban, Juan Ignacio

AU - Otero, Teresa

AU - Sauleda, Silvia

AU - Bes, Marta

AU - Esteban, Rafael

AU - Guardia, Jaume

AU - Quer, Josep

PY - 2008/1/20

Y1 - 2008/1/20

N2 - An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. © 2007 Elsevier Inc. All rights reserved.

AB - An increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in vivo and in vitro. A specific mutation, A156T has been shown to confer high-level resistance to several such agents (BILN2061, VX-950, SCH446211 (SCH6) and SCH503034). Here we report the presence of the A156T mutation in close to 1% of NS3 sequences within the liver quasispecies of a chronic hepatitis C patient never treated with anti-NS3-protease inhibitors. © 2007 Elsevier Inc. All rights reserved.

KW - HCV-NS3

KW - Inhibitor

KW - Mutant

KW - Patient

KW - Resistant

KW - Untreated

U2 - 10.1016/j.virol.2007.10.006

DO - 10.1016/j.virol.2007.10.006

M3 - Article

SN - 0042-6822

VL - 370

SP - 237

EP - 245

JO - Virology

JF - Virology

IS - 2

ER -

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this